SCHEMBL23716019

SCHEMBL23716019

CSC(=O)N1CCCc2cccc(C)c21

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.58
ALOX12 P18054 1/20 0.52
CNR2 P34972 1/20 0.47
NOTUM Q6P988 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 3/20 0.42
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MGLL Q99685 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14591324 0.83 NOTUM (0.59) L3MBTL1ALOX12CNR2NOTUMSMN1; SMN2
SCHEMBL28598365 0.83 L3MBTL1 (0.59) L3MBTL1ALOX12CNR2NOTUMSMN1; SMN2
SCHEMBL10914380 0.82 L3MBTL1 (0.57) L3MBTL1ALOX12CNR2NOTUMSMN1; SMN2
SCHEMBL14261668 0.79 L3MBTL1 (0.55) L3MBTL1ALOX12CNR2NOTUMSMN1; SMN2
SCHEMBL26620270 0.79 L3MBTL1 (0.55) L3MBTL1ALOX12CNR2NOTUMSMN1; SMN2
SCHEMBL19447114 0.79 NOTUM (0.55) L3MBTL1ALOX12CNR2NOTUMSMN1; SMN2
SCHEMBL342396 0.78 L3MBTL1 (0.54) L3MBTL1ALOX12CNR2NOTUMSMN1; SMN2
SCHEMBL4868965 0.74 L3MBTL1 (0.72) L3MBTL1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL7163398 0.73 NOTUM (0.69) L3MBTL1ALOX12CNR2NOTUMALDH1A1
SCHEMBL15545123 0.73 CNR2 (0.86) L3MBTL1ALOX12CNR2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021152149-A1 RAS INHIBITORS AND METHODS OF USING THE SAME JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2021-08-05 WO disclosed